Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladder dysfunction
Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladder dysfunction
复制标题
静脉注射阿夫唑嗪对神经源性膀胱功能障碍患者尿道压力的影响
DOI：
10.1002/nau.1930150203
复制
发表时间：
1996
影响因子：
2
通讯作者：
E. Mcguire
中科院分区：
文献类型：
--
作者：
M. Perrigot;M. Delauche‐Cavallier;G. Amarenco;C. Geffriaud;A. Stalla‐Bourdillon;P. Costa;E. Mcguire
为了评估单次静脉（IV）注射阿夫唑嗪（一种选择性α 1受体阻滞剂）降低症状性神经源性膀胱功能障碍（NBD）患者高尿道张力的能力，163例患者（平均最大尿道压[MUP] 108 ± 46 cm H2O）入组一项双盲、安慰剂对照、平行组试验，随机分配接受0.5 mg（n = 45）、1 mg（n = 41）、2 mg（n = 39）阿夫唑嗪或安慰剂（n = 38）。与安慰剂组（23 ± 30 cm H2O）相比，1 mg和2 mg阿夫唑嗪组的MUP降低具有剂量依赖性和统计学显著性（P <0.05）（分别为43 ± 28 cm H2O和46 ± 27 cm H2O较基线降低）。2 mg剂量水平是最有效的，分别导致69和44%的患者的MUP降低30%或50%。所有3种阿夫唑嗪剂量水平的安全性均令人满意，且与安慰剂相当。
In order to assess the ability of a single intravenous (IV) injection of alfuzosin, a selective alpha‐1 blocker, in reducing high urethral tone in patients with symptomatic neurogenic bladder dysfunction (NBD), 163 patients (mean maximal urethral pressure [MUP] 108 ± 46 cm H2O) were enrolled in a double‐blind, placebo‐controlled, parallel‐group trial and were randomly allocated to receive 0.5 mg (n = 45), 1 mg (n = 41), 2 mg (n = 39) alfuzosin or placebo (n = 38). The decrease in MUP was dose‐dependent and statistically significant (P ⩽ 0.05) for 1 and 2 mg alfuzosin (respectively, 43 ± 28 cm H2O and 46 ± 27 cm H2O decreases vs. baseline) in comparison with placebo (23 ± 30 cm H2O). The 2 mg dose level was the most effective leading to a ⩾30 or 50% decrease in MUP in, respectively, 69 and 44% of patients. The safety of all three alfuzosin dose levels was satisfactory and comparable to placebo.
影响因子：
6.6
作者：
STERNBERG, CN;YAGODA, A;WHITMORE, WF
通讯作者：
WHITMORE, WF